Actuate Therapeutics, Inc. recently held a Key Opinion Leader $(KOL)$ event, during which President and CEO Daniel Schmitt discussed the significant milestone achieved in their Phase 2 study of elraglusib for the first-line treatment of metastatic pancreatic cancer. The event featured insights from four renowned clinical leaders in gastrointestinal oncology, including Dr. Deva Mahalingam, who presented the topline data of the 1801 3b study. The full transcript of the event is available for viewing. For those interested, the replay can be accessed [here](https://lifescievents.com/event/actuate/).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.